[1]张煜敏, 张桢烨, 钱玲玲, 等. 槲皮素通过AKT/FOXO3信号通路保护糖尿病大鼠心肌细胞[J]. 江苏大学学报(医学版), 2021, 31(3): 185-189.
[2]Yang S, Fei X, Lu Y, et al. MiRNA214 suppresses oxidative stress in diabetic nephropathy via the ROS/Akt/mTOR signaling pathway and uncoupling protein 2[J]. Exp Ther Med, 2019, 17(5): 3530-3538.
[3]Lv M, Chen Z, Hu G, et al. Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives[J]. Drug Discov Today, 2015, 20(3): 332-346.
[4]洪金妮, 黎巍威, 王学美. 糖尿病肾病中足细胞损伤的信号通路及中药的干预研究进展[J]. 中药药理与临床, 2017, 33(3): 215-219.
[5]Wang G, Yan Y, Xu N, et al. Upregulation of microRNA424 relieved diabetic nephropathy by targeting rictor through mTOR complex2/protein kinase B signaling[J]. J Cell Physiol, 2019, 234(7): 11646-11653.
[6]Zhao SM, Zhang T, Qiu Q, et al. MiRNA337 leads to podocyte injury in mice with diabetic nephropathy[J]. Eur Rev Med Pharmacol Sci, 2019, 23(19): 8485-8492.
[7]Yarahmadi A, Shahrokhi SZ, Mostafavi PZ, et al. MicroRNAs in diabetic nephropathy: From molecular mechanisms to new therapeutic targets of treatment[J]. Biochem Pharmacol, 2021, 189: 114301.
[8]邵晓娜, 耿嘉男, 胡彦武, 等. MicroRNA与糖尿病肾病关系的探讨[J]. 中国实验诊断学, 2015, 19(11): 1974-1977.
[9]杨烽, 张倩, 郑宗基, 等. MicroRNA在糖尿病肾病临床诊断中的应用与进展[J]. 现代诊断与治疗, 2018, 29(4): 529-531.
[10]左熠, 何笑云, 周素娴. MALAT1在糖尿病及其微血管并发症中的作用新进展[J]. 江苏大学学报(医学版), 2021, 31(3): 200-204.
[11]Nascimento LRD, Domingueti CP. MicroRNAs: new biomarkers and promising therapeutic targets for diabetic kidney disease[J]. J Bras Nefrol, 2019, 41(3): 412-422.
[12]Dewanjee S, Bhattacharjee N. MicroRNA: A new generation therapeutic target in diabetic nephropathy[J]. Biochem Pharmacol, 2018, 155: 32-47.
[13]Tang B, Li W, Ji T, et al. CircAKT3 inhibits the accumulation of extracellular matrix of mesangial cells in diabetic nephropathy via modulating miR2963p/Ecadherin signals[J]. J Cell Mol Med, 2020, 24(15): 8779-8788.
[14]Bracken CP, Gregory PA, Kolesnikoff N, et al. A doublenegative feedback loop between ZEB1SIP1 and the microRNA200 family regulates epithelialmesenchymal transition[J]. Cancer Res, 2008, 68(19): 7846-7854.
[15]Chung AC, Hung XR, Meng HY, et al. MiR192 mediates TGFβ/Smad3driven renal fibrosis[J]. J Am Soc Nephrol, 2010, 21(8): 1317-1325.
[16]Park JT, Kato M, Yuan H, et al. FOG2 protein downregulation by transforming growth factorβ1induced microRNA200b/c leads to Akt kinase activation and glomerular mesangial hypertrophy related to diabetic nephropathy[J]. J Biol Chem, 2013, 288(31): 22469-22480.
[17]Sun Z, Ma Y, Chen F, et al. MiR133b and miR199b knockdown attenuate TGFβ1induced epithelial to mesenchymal transition and renal fibrosis by targeting SIRT1 in diabetic nephropathy[J]. Eur J Pharmacol, 2018, 837: 96-104.
[18]Yao T, Zha D, Gao P, et al. MiR874 alleviates renal injury and inflammatory response in diabetic nephropathy through targeting tolllike receptor4[J]. J Cell Physiol, 2018, 234(1): 871-879.
[19]He M, Wang J, Yin Z, et al. MiR320a induces diabetic nephropathy via inhibiting MafB[J]. Aging, 2019, 11(10): 3055-3079.
[20]Bhatt K, Lanting LL, Jia Y, et al. Antiinflammatory role of microRNA146a in the pathogenesis of diabetic nephropathy[J]. J Am Soc Nephrol, 2016, 27(8): 2277-2288.
[21]Lee HW, Khan SQ, Khaliqdina S, et al. Absence of miR146a in podocytes increases risk of diabetic glomerulopathy via upregulation of ErbB4 and Notch1[J]. J Biol Chem, 2017, 292(2): 732-747.
[22]Zha F, Bai L, Tang B, et al. MicroRNA503 contributes to podocyte injury via targeting E2F3 in diabetic nephropathy[J]. J Cell Biochem, 2019, 120(8): 12574-12581.
[23]Wang X, Lin B, Nie L, et al. MicroRNA20b contributes to high glucoseinduced podocyte apoptosis by targeting SIRT7[J]. Mol Med Rep, 2017, 16(4): 5667-5674.
[24]许薇, 姚少侠, 苟小林. 血清miRNA21和miRNA192表达与糖尿病肾病的相关性研究[J]. 河北医科大学学报, 2019, 40(12): 1460-1464.
[25]Chen X, Zhao L, Xing Y, et al. Downregulation of microRNA21 reduces inflammation and podocyte apoptosis in diabetic nephropathy by relieving the repression of TIMP3 expression[J]. Biomed Pharmacother, 2018, 108: 7-14.
[26]Long J, Wang Y, Wang W, et al. MicroRNA29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy[J]. J Biol Chem, 2011, 286(13): 11837-11848.
[27]Guo J, Li J, Zhao J, et al. MiRNA29c regulates the expression of inflammatory cytokines in diabetic nephropathy by targeting tristetraprolin[J]. Sci Rep, 2017, 7(1): 2314.
[28]Li YL, Liu LN, Huang L, et al. Niao du kang mixture increases the expression of mir1295p to relieve renal fibrosis[J]. Evid Based Complement Alternat Med, 2020, 2020: 1841890.
[29]Sun F, Yu PF, Wang D, et al. MicroRNA488 regulates diabetic nephropathy via TGFβ1 pathway[J]. Eur Rev Med Pharmacol Sci, 2019, 23(10): 4333-4340.
[30]Xu ZJ, Shu S, Li ZJ, et al. Liuwei Dihuang pill treats diabetic nephropathy in rats by inhibiting of TGFβ/SMADS, MAPK, and NFκB and upregulating expression of cytoglobin in renal tissues[J]. Medicine (Baltimore), 2017, 96(3): e5879.
[31]Zhong X, Chung AC, Chen HY, et al. MiR21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes[J]. Diabetologia, 2013, 56(3): 663-674.
[32]Chen H, Zhong X, Huang X, et al. MicroRNA29b inhibits diabetic nephropathy in db/db mice[J]. Mol Ther, 2014, 22(4): 842-853.
[33]He F, Peng F, Xia X, et al. MiR135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1[J]. Diabetologia, 2014, 57(8): 1726-1736.
[34]王晓莉, 刘洁婷, 张春雷, 等. MicroRNA25通过调控MAP2K4抑制糖尿病肾病纤维化的研究[J]. 医药导报, 2015, 34(4): 425-431.
[35]Zhou J, Shen X, Zhu C, et al. MiR4553p suppresses renal fibrosis through repression of ROCK2 expression in diabetic nephropathy[J]. Biochem Biophys Res Commun, 2018, 503(2): 977-983.
[36]Jiang ZH, Tang YZ, Song HN, et al. MiRNA342 suppresses renal interstitial fibrosis in diabetic nephropathy by targeting SOX6[J]. Int J Mol Med, 2020, 45(1): 45-52.